S

Sanofi

Global pharma company; vaccines and R&D

Rare Hematology Area Business Manager - Allergy/Immunology

Full-TimeUpdated on 10/23/2026Deadline 12/15/26
$125.3k - $180.9k
Mid
Bachelor's
Remote in USA
RemoteMust reside within or in close proximity to the assigned territory.
Sales & Account ManagementField Sales

About the job

Requirements
  • A B.A. or B.S. degree is required.
  • At least 3 years of experience in biotechnology or pharmaceutical sales is required.
  • Must reside within or in close proximity to the assigned territory.
  • Must have a valid driver's license and be willing to travel up to 50% for the field-based role.
Responsibilities
  • Own sales execution for the allergy/immunology customer segment within the assigned territory, with responsibility for AYVAKIT performance across prioritized specialists and accounts.
  • Identify and engage allergists, immunologists, and broader care-team members who are key treatment decision makers, and conduct customer meetings within the territory using approved resources and messaging.
  • Identify and engage customers in emerging specialties, such as dermatology and gastroenterology, to increase awareness of systemic mastocytosis and AYVAKIT.
  • Build relationships and manage accounts by engaging physicians, advanced practice providers, nursing, pharmacy, and practice leadership.
  • Apply therapeutic, product, and healthcare market expertise to compliant customer engagement, business planning, and actionable field insights.
  • Develop and execute territory business plans to achieve performance objectives.
  • Lead market development in the territory by increasing disease awareness, supporting appropriate patient identification and referral, and addressing healthcare provider educational gaps across systemic mastocytosis patient journeys.
  • Conduct formal and informal presentations and communicate complex clinical information to physicians in large academic centers, hospitals, and large group practices in a professional, compliant, ethical, and effective manner.
  • Build and maintain relationships with key accounts and customers, coordinating with cross-functional stakeholders as needed to manage relationships of national or regional relevance.
  • Partner with Key Account Managers to align healthcare-provider-level execution with account access, pull-through priorities, and overall account strategy.
  • Identify and escalate institutional barriers and support coordinated engagement at priority hospitals, health systems, integrated delivery networks, and community practices.
  • Communicate with the Regional Business Director, peer Area Business Managers, and other internal stakeholders by sharing customer insights, market trends, competitive activity, and emerging business opportunities.
  • Collaborate with cross-functional team members to address customer needs compliantly and with urgency.
  • Proactively identify new opportunities and apply customer insights to develop, execute, and refine territory approaches.
  • Use customer relationship management systems, customer segmentation, sales analytics, and other approved analytical tools to understand business trends, prioritize activity, and meet target key performance indicators.
  • Represent Sanofi at hematology/oncology congresses and local professional association meetings.
Desired Qualifications
  • A degree in Health Sciences, Business, Marketing, or Accounting is preferred.
  • At least 5 years of Allergy/Immunology and/or rare disease experience is strongly preferred.
  • Sales launch experience with complex specialty products.
  • Consistent success driving above-plan sales results within a specific region or territory.
  • Experience promoting multiple products while balancing distinct disease-state and customer priorities within one territory.
  • Understanding of disease-modifying therapies with a requisite diagnostic component and ability to navigate patient pull-through in complex market-access environments.
  • Ability to use educational resources, data, and programs to support a positive patient and provider experience.
  • Interpersonal and communication skills to form trusting partnerships and drive performance.
  • Analytical and problem-solving skills, including the ability to identify and act on creative solutions.
  • Ability to establish credibility, connect insights, and align stakeholders to support adoption of new products, methods, and technologies.
  • Ability to collaborate with a broad range of stakeholders, gain consensus, and act independently in a fast-paced environment.
  • Flexibility and ability to plan and adapt to changing market conditions.
  • Commitment to patient focus, urgency, high performance, results, compliance, integrity, and a strong work ethic.

About the company

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Company News

Associated Press
Oct 19th, 2026
Enable Injections wins first Japan approval for enFuse on-body injector via Sanofi's CirCLIQ

Enable Injections has won its first commercial product approval in Japan. The country's Ministry of Health, Labour and Welfare approved the company's enFuse On-Body Delivery System through Sanofi's CirCLIQ Injector. The device delivers a subcutaneous form of Sarclisa (isatuximab) with the push of a button, for treating multiple myeloma. It is the first anticancer treatment given through an on-body injector in Japan. The approval follows recent clearances in the US and Europe. Japan approved Sarclisa SC in June 2026, backed by the IRAKLIA phase 3 study, which showed the subcutaneous form was non-inferior to intravenous delivery. "We're proud to partner with Sanofi to bring our enFuse technology to patients in Japan," said Michael D. Hooven, chairman and chief executive officer of Enable.

Yahoo Finance
Oct 1st, 2026
Sanofi, Regeneron expand alliance in up to $8B deal for immunology drugs

France's Sanofi and US-based Regeneron Pharmaceuticals will expand their 20-year partnership to jointly develop and market immunology medicines in a deal worth up to $8 billion. Regeneron will receive $1 billion upfront, with potential additional payments of up to $7 billion tied to development, regulatory, and commercial targets. The collaboration will add four next-generation immunology drug candidates invented by Regeneron, with one currently in early-stage trials for eczema. The companies will equally share development costs and future profits from new drugs, whilst their existing profit-sharing agreement for top-selling medicine Dupixent remains unchanged. The deal settles prior litigation between the companies and marks an early move by Sanofi's new chief executive Belen Garijo to strengthen the company's pipeline.

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Vicebio

Sanofi completes acquisition of Vicebio Paris, December 4, 2025. Sanofi announces the completion of its acquisition of Vicebio Ltd (“Vicebio”). This acquisition brings an early-stage combination...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes acquisition of Blueprint Medicines

Sanofi completes acquisition of Blueprint Medicines Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its...

Sanofi
Sep 20th, 2026
Press Release: Sanofi completes the acquisition of Dynavax

Sanofi completes the acquisition of Dynavax Paris, February 10, 2026. Sanofi today announced that it has completed the acquisition of Dynavax Technologies Corporation (Dynavax). The acquisition...